We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
Read MoreHide Full Article
Crinetics Pharmaceuticals’ (CRNX - Free Report) shares gained 19.1% on Mar 19 after the company reported positive top-line data from the second (PATHFNDR-2) of two late-stage studies evaluating the efficacy and safety of lead candidate, paltusotine, for the treatment of acromegaly.
Acromegaly is a rare endocrine disease generally caused by a pituitary adenoma, which is a non-cancerous tumor in the pituitary that secretes growth hormone.
The PATHFNDR-2 study is evaluating paltusotine, an oral SST2 agonist, in participants with acromegaly who are treatment-naïve or not currently receiving medical therapy.
Per the data readout, the phase III PATHFNDR-2 study met its primary endpoint, with statistical significance, observing that 56% of patients treated with paltusotine achieved an insulin-like growth factor 1 (IGF-1) level ≤ 1.0 times the upper limit of normal (xULN) compared with those who received placebo (5%). Crinetics also reported that all secondary endpoints met statistical significance.
Additionally, CRNX stated that the candidate was overall well tolerated with no serious adverse events in the PATHFNDR-2 study.
Management believes that the encouraging data from the PATHFNDR-2 study reaffirms paltusotine’s potential to provide both symptom control as well as biochemical control in patients who are not currently on pharmacologic treatment for acromegaly.
In the past year, shares of Crinetics have skyrocketed 179.4% against the industry’s 5% decline.
Image Source: Zacks Investment Research
We would like to remind the investors that in September 2023, CRNX reported positive top-line data from the first late-stage study of paltusotine for the treatment of acromegaly, PATHFNDR-1.
The phase III PATHFNDR-1 study evaluated paltusotine in patients with acromegaly who were switching from current standard-of-care treatment, octreotide or lanreotide depot monotherapy.
Per the data readout, the study met its primary endpoint with statistical significance, observing that 83% of participants taking paltusotine maintained an IGF-1 level ≤ 1.0xULN compared with those who received placebo (4%). All secondary endpoints in the phase III PATHFNDR-1 study also met statistical significance.
Positive data readout from both the phase III PATHFNDR-1 and PATHFNDR-2 studies bolsters paltusotine’s potential in becoming a new treatment option for all patients living with acromegaly, subject to approval.
Crinetics is currently gearing up to submit a regulatory application to the FDA seeking approval of paltusotine for the acromegaly indication in the second half of 2024. The company aims to potentially launch the product in the U.S. market in 2025.
Notably, CRNX is currently evaluating paltusotine in a separate mid-stage study for the treatment of Carcinoid syndrome.
Crinetics Pharmaceuticals, Inc. Price and Consensus
In the past 30 days, the Zacks Consensus Estimate for ADMA Biologics’ 2024 earnings per share (EPS) has increased from 22 cents to 30 cents. During the same period, the estimate for ADMA’s 2025 EPS has increased from 32 cents to 50 cents. In the past year, shares of ADMA have surged 99.7%.
ADMA beat estimates in three of the trailing four quarters and matched in one, delivering an average earnings surprise of 85%.
In the past 30 days, the Zacks Consensus Estimate for FibroGen’s 2024 loss per share has narrowed from $1.14 to $1.09. During the same period, the estimate for FibroGen’s 2025 loss per share is pegged at 6 cents. In the past year, shares of FGEN have plunged 87.9%.
FGEN beat estimates in two of the trailing four quarters, missing the mark on the other two occasions, delivering an average negative surprise of 2.26%.
In the past 30 days, the Zacks Consensus Estimate for Adicet Bio’s 2024 loss per share has remained constant at $1.81. During the same period, the consensus estimate for Adicet’s 2025 loss per share has remained constant at $1.87. In the past year, shares of ACET have plunged 69.1%.
ACET beat estimates in three of the trailing four quarters, missing the mark on one occasion, delivering an average negative surprise of 0.17%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Crinetics (CRNX) Up as Second Acromegaly Study Meets Goals
Crinetics Pharmaceuticals’ (CRNX - Free Report) shares gained 19.1% on Mar 19 after the company reported positive top-line data from the second (PATHFNDR-2) of two late-stage studies evaluating the efficacy and safety of lead candidate, paltusotine, for the treatment of acromegaly.
Acromegaly is a rare endocrine disease generally caused by a pituitary adenoma, which is a non-cancerous tumor in the pituitary that secretes growth hormone.
The PATHFNDR-2 study is evaluating paltusotine, an oral SST2 agonist, in participants with acromegaly who are treatment-naïve or not currently receiving medical therapy.
Per the data readout, the phase III PATHFNDR-2 study met its primary endpoint, with statistical significance, observing that 56% of patients treated with paltusotine achieved an insulin-like growth factor 1 (IGF-1) level ≤ 1.0 times the upper limit of normal (xULN) compared with those who received placebo (5%). Crinetics also reported that all secondary endpoints met statistical significance.
Additionally, CRNX stated that the candidate was overall well tolerated with no serious adverse events in the PATHFNDR-2 study.
Management believes that the encouraging data from the PATHFNDR-2 study reaffirms paltusotine’s potential to provide both symptom control as well as biochemical control in patients who are not currently on pharmacologic treatment for acromegaly.
In the past year, shares of Crinetics have skyrocketed 179.4% against the industry’s 5% decline.
Image Source: Zacks Investment Research
We would like to remind the investors that in September 2023, CRNX reported positive top-line data from the first late-stage study of paltusotine for the treatment of acromegaly, PATHFNDR-1.
The phase III PATHFNDR-1 study evaluated paltusotine in patients with acromegaly who were switching from current standard-of-care treatment, octreotide or lanreotide depot monotherapy.
Per the data readout, the study met its primary endpoint with statistical significance, observing that 83% of participants taking paltusotine maintained an IGF-1 level ≤ 1.0xULN compared with those who received placebo (4%). All secondary endpoints in the phase III PATHFNDR-1 study also met statistical significance.
Positive data readout from both the phase III PATHFNDR-1 and PATHFNDR-2 studies bolsters paltusotine’s potential in becoming a new treatment option for all patients living with acromegaly, subject to approval.
Crinetics is currently gearing up to submit a regulatory application to the FDA seeking approval of paltusotine for the acromegaly indication in the second half of 2024. The company aims to potentially launch the product in the U.S. market in 2025.
Notably, CRNX is currently evaluating paltusotine in a separate mid-stage study for the treatment of Carcinoid syndrome.
Crinetics Pharmaceuticals, Inc. Price and Consensus
Crinetics Pharmaceuticals, Inc. price-consensus-chart | Crinetics Pharmaceuticals, Inc. Quote
Zacks Rank and Stocks to Consider
Crinetics currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the drug/biotech industry are ADMA Biologics (ADMA - Free Report) , FibroGen (FGEN - Free Report) and Adicet Bio, Inc. (ACET - Free Report) . While ADMA sports a Zacks Rank #1 (Strong Buy), FGEN and ACET carry a Zacks Rank #2 (Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 30 days, the Zacks Consensus Estimate for ADMA Biologics’ 2024 earnings per share (EPS) has increased from 22 cents to 30 cents. During the same period, the estimate for ADMA’s 2025 EPS has increased from 32 cents to 50 cents. In the past year, shares of ADMA have surged 99.7%.
ADMA beat estimates in three of the trailing four quarters and matched in one, delivering an average earnings surprise of 85%.
In the past 30 days, the Zacks Consensus Estimate for FibroGen’s 2024 loss per share has narrowed from $1.14 to $1.09. During the same period, the estimate for FibroGen’s 2025 loss per share is pegged at 6 cents. In the past year, shares of FGEN have plunged 87.9%.
FGEN beat estimates in two of the trailing four quarters, missing the mark on the other two occasions, delivering an average negative surprise of 2.26%.
In the past 30 days, the Zacks Consensus Estimate for Adicet Bio’s 2024 loss per share has remained constant at $1.81. During the same period, the consensus estimate for Adicet’s 2025 loss per share has remained constant at $1.87. In the past year, shares of ACET have plunged 69.1%.
ACET beat estimates in three of the trailing four quarters, missing the mark on one occasion, delivering an average negative surprise of 0.17%.